MONTREAL, QUEBEC--(CCNMatthews - May 24, 2006) - CV Technologies Inc. (TSX:CVQ) today reported on the successful completion at McGill University of a pre-clinical cancer study involving CVT-E002 demonstrating positive results. The results support the hypothesis that CVT-E002 may have potential as a cancer therapy and may also support the immune system during cancer treatment. The study, launched in November 2004, was led by Dr. Sandra Miller, a professor in the Department of Anatomy and Biology in the Faculty of Medicine at McGill University in Montreal. Dr. Miller has long studied and conducted research of stem cells and the immune system including the body’s natural killer (NK) cells.
